 | • レポートコード：MRC23Q37071 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のジピン系降圧剤市場について調査・分析し、世界のジピン系降圧剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（ニフェジピン、アムロジピンベシル酸塩、フェリジピン、ベニジピン、その他）、用途別セグメント分析（病院、クリニック）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Johnson & Johnson、Merck & Co., Inc.、NOVARTIS、Astrazeneca、Bayer、Kyowa Hakko Kogyo、Zuventus Health care ltd、JB Chemicals and Pharmaceuticals Ltd、Boehringer Ingelheim、GSK、Daiichi-Sankyo、fujipharmaなどが含まれています。 世界のジピン系降圧剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ジピン系降圧剤市場規模を推定する際に考慮しました。本レポートは、ジピン系降圧剤の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ジピン系降圧剤に関するビジネス上の意思決定に役立てることを目的としています。 ・ジピン系降圧剤市場の概要 - 製品の定義 - ジピン系降圧剤のタイプ別セグメント - 世界のジピン系降圧剤市場規模：タイプ別分析（ニフェジピン、アムロジピンベシル酸塩、フェリジピン、ベニジピン、その他） - ジピン系降圧剤の用途別セグメント - 世界のジピン系降圧剤市場規模：用途別分析（病院、クリニック） - 世界のジピン系降圧剤市場規模予測（2018年-2029年） - ジピン系降圧剤の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - ジピン系降圧剤市場の競争状況およびトレンド ・ジピン系降圧剤の地域別市場規模 - 北米のジピン系降圧剤市場規模（2018年-2029年） - アメリカのジピン系降圧剤市場規模（2018年-2029年） - ヨーロッパのジピン系降圧剤市場規模（2018年-2029年） - アジア太平洋のジピン系降圧剤市場規模（2018年-2029年） - 中国のジピン系降圧剤市場規模（2018年-2029年） - 日本のジピン系降圧剤市場規模（2018年-2029年） - 韓国のジピン系降圧剤市場規模（2018年-2029年） - インドのジピン系降圧剤市場規模（2018年-2029年） - オーストラリアのジピン系降圧剤市場規模（2018年-2029年） - 中南米のジピン系降圧剤市場規模（2018年-2029年） - 中東・アフリカのジピン系降圧剤市場規模（2018年-2029年） ・タイプ別セグメント：ニフェジピン、アムロジピンベシル酸塩、フェリジピン、ベニジピン、その他 - 世界のジピン系降圧剤のタイプ別販売量（2018年-2023年） - 世界のジピン系降圧剤のタイプ別売上（2018年-2023年） - 世界のジピン系降圧剤のタイプ別価格 ・用途別セグメント：病院、クリニック - 世界のジピン系降圧剤の用途別販売量（2018年-2023年） - 世界のジピン系降圧剤の用途別売上（2018年-2023年） - 世界のジピン系降圧剤の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Johnson & Johnson、Merck & Co., Inc.、NOVARTIS、Astrazeneca、Bayer、Kyowa Hakko Kogyo、Zuventus Health care ltd、JB Chemicals and Pharmaceuticals Ltd、Boehringer Ingelheim、GSK、Daiichi-Sankyo、fujipharma ・産業チェーンと販売チャネルの分析 - ジピン系降圧剤産業チェーン分析 - ジピン系降圧剤の主要原材料 - ジピン系降圧剤の販売チャネル - ジピン系降圧剤のディストリビューター - ジピン系降圧剤の主要顧客 ・ジピン系降圧剤市場ダイナミクス - ジピン系降圧剤の業界動向 - ジピン系降圧剤市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Dipine Antihypertensive Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Dipine Antihypertensive Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Dipine Antihypertensive Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Dipine Antihypertensive Drugs include Johnson & Johnson, Merck & Co., Inc., NOVARTIS, Astrazeneca, Bayer, Kyowa Hakko Kogyo, Zuventus Health care ltd, JB Chemicals and Pharmaceuticals Ltd and Boehringer Ingelheim, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dipine Antihypertensive Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dipine Antihypertensive Drugs.
The Dipine Antihypertensive Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Dipine Antihypertensive Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dipine Antihypertensive Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Johnson & Johnson
Merck & Co., Inc.
NOVARTIS
Astrazeneca
Bayer
Kyowa Hakko Kogyo
Zuventus Health care ltd
JB Chemicals and Pharmaceuticals Ltd
Boehringer Ingelheim
GSK
Daiichi-Sankyo
fujipharma
Segment by Type
Nifedipine
Amlodipine Besylate
Felidipine
Benidipine
Other
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dipine Antihypertensive Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dipine Antihypertensive Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Dipine Antihypertensive Drugs Market Overview
1.1 Product Overview and Scope of Dipine Antihypertensive Drugs
1.2 Dipine Antihypertensive Drugs Segment by Type
1.2.1 Global Dipine Antihypertensive Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Nifedipine
1.2.3 Amlodipine Besylate
1.2.4 Felidipine
1.2.5 Benidipine
1.2.6 Other
1.3 Dipine Antihypertensive Drugs Segment by Application
1.3.1 Global Dipine Antihypertensive Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Dipine Antihypertensive Drugs Market Size Estimates and Forecasts
1.4.1 Global Dipine Antihypertensive Drugs Revenue 2018-2029
1.4.2 Global Dipine Antihypertensive Drugs Sales 2018-2029
1.4.3 Global Dipine Antihypertensive Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Dipine Antihypertensive Drugs Market Competition by Manufacturers
2.1 Global Dipine Antihypertensive Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Dipine Antihypertensive Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Dipine Antihypertensive Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Dipine Antihypertensive Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Dipine Antihypertensive Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dipine Antihypertensive Drugs, Product Type & Application
2.7 Dipine Antihypertensive Drugs Market Competitive Situation and Trends
2.7.1 Dipine Antihypertensive Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Dipine Antihypertensive Drugs Players Market Share by Revenue
2.7.3 Global Dipine Antihypertensive Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dipine Antihypertensive Drugs Retrospective Market Scenario by Region
3.1 Global Dipine Antihypertensive Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Dipine Antihypertensive Drugs Global Dipine Antihypertensive Drugs Sales by Region: 2018-2029
3.2.1 Global Dipine Antihypertensive Drugs Sales by Region: 2018-2023
3.2.2 Global Dipine Antihypertensive Drugs Sales by Region: 2024-2029
3.3 Global Dipine Antihypertensive Drugs Global Dipine Antihypertensive Drugs Revenue by Region: 2018-2029
3.3.1 Global Dipine Antihypertensive Drugs Revenue by Region: 2018-2023
3.3.2 Global Dipine Antihypertensive Drugs Revenue by Region: 2024-2029
3.4 North America Dipine Antihypertensive Drugs Market Facts & Figures by Country
3.4.1 North America Dipine Antihypertensive Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Dipine Antihypertensive Drugs Sales by Country (2018-2029)
3.4.3 North America Dipine Antihypertensive Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Dipine Antihypertensive Drugs Market Facts & Figures by Country
3.5.1 Europe Dipine Antihypertensive Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Dipine Antihypertensive Drugs Sales by Country (2018-2029)
3.5.3 Europe Dipine Antihypertensive Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dipine Antihypertensive Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Dipine Antihypertensive Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Dipine Antihypertensive Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Dipine Antihypertensive Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Dipine Antihypertensive Drugs Market Facts & Figures by Country
3.7.1 Latin America Dipine Antihypertensive Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Dipine Antihypertensive Drugs Sales by Country (2018-2029)
3.7.3 Latin America Dipine Antihypertensive Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dipine Antihypertensive Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Dipine Antihypertensive Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Dipine Antihypertensive Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Dipine Antihypertensive Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dipine Antihypertensive Drugs Sales by Type (2018-2029)
4.1.1 Global Dipine Antihypertensive Drugs Sales by Type (2018-2023)
4.1.2 Global Dipine Antihypertensive Drugs Sales by Type (2024-2029)
4.1.3 Global Dipine Antihypertensive Drugs Sales Market Share by Type (2018-2029)
4.2 Global Dipine Antihypertensive Drugs Revenue by Type (2018-2029)
4.2.1 Global Dipine Antihypertensive Drugs Revenue by Type (2018-2023)
4.2.2 Global Dipine Antihypertensive Drugs Revenue by Type (2024-2029)
4.2.3 Global Dipine Antihypertensive Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Dipine Antihypertensive Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Dipine Antihypertensive Drugs Sales by Application (2018-2029)
5.1.1 Global Dipine Antihypertensive Drugs Sales by Application (2018-2023)
5.1.2 Global Dipine Antihypertensive Drugs Sales by Application (2024-2029)
5.1.3 Global Dipine Antihypertensive Drugs Sales Market Share by Application (2018-2029)
5.2 Global Dipine Antihypertensive Drugs Revenue by Application (2018-2029)
5.2.1 Global Dipine Antihypertensive Drugs Revenue by Application (2018-2023)
5.2.2 Global Dipine Antihypertensive Drugs Revenue by Application (2024-2029)
5.2.3 Global Dipine Antihypertensive Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Dipine Antihypertensive Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Johnson & Johnson Dipine Antihypertensive Drugs Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Merck & Co., Inc.
6.2.1 Merck & Co., Inc. Corporation Information
6.2.2 Merck & Co., Inc. Description and Business Overview
6.2.3 Merck & Co., Inc. Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co., Inc. Dipine Antihypertensive Drugs Product Portfolio
6.2.5 Merck & Co., Inc. Recent Developments/Updates
6.3 NOVARTIS
6.3.1 NOVARTIS Corporation Information
6.3.2 NOVARTIS Description and Business Overview
6.3.3 NOVARTIS Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 NOVARTIS Dipine Antihypertensive Drugs Product Portfolio
6.3.5 NOVARTIS Recent Developments/Updates
6.4 Astrazeneca
6.4.1 Astrazeneca Corporation Information
6.4.2 Astrazeneca Description and Business Overview
6.4.3 Astrazeneca Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astrazeneca Dipine Antihypertensive Drugs Product Portfolio
6.4.5 Astrazeneca Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Corporation Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bayer Dipine Antihypertensive Drugs Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Kyowa Hakko Kogyo
6.6.1 Kyowa Hakko Kogyo Corporation Information
6.6.2 Kyowa Hakko Kogyo Description and Business Overview
6.6.3 Kyowa Hakko Kogyo Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Kyowa Hakko Kogyo Dipine Antihypertensive Drugs Product Portfolio
6.6.5 Kyowa Hakko Kogyo Recent Developments/Updates
6.7 Zuventus Health care ltd
6.6.1 Zuventus Health care ltd Corporation Information
6.6.2 Zuventus Health care ltd Description and Business Overview
6.6.3 Zuventus Health care ltd Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Zuventus Health care ltd Dipine Antihypertensive Drugs Product Portfolio
6.7.5 Zuventus Health care ltd Recent Developments/Updates
6.8 JB Chemicals and Pharmaceuticals Ltd
6.8.1 JB Chemicals and Pharmaceuticals Ltd Corporation Information
6.8.2 JB Chemicals and Pharmaceuticals Ltd Description and Business Overview
6.8.3 JB Chemicals and Pharmaceuticals Ltd Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 JB Chemicals and Pharmaceuticals Ltd Dipine Antihypertensive Drugs Product Portfolio
6.8.5 JB Chemicals and Pharmaceuticals Ltd Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Corporation Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Boehringer Ingelheim Dipine Antihypertensive Drugs Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 GSK Dipine Antihypertensive Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Daiichi-Sankyo
6.11.1 Daiichi-Sankyo Corporation Information
6.11.2 Daiichi-Sankyo Dipine Antihypertensive Drugs Description and Business Overview
6.11.3 Daiichi-Sankyo Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Daiichi-Sankyo Dipine Antihypertensive Drugs Product Portfolio
6.11.5 Daiichi-Sankyo Recent Developments/Updates
6.12 fujipharma
6.12.1 fujipharma Corporation Information
6.12.2 fujipharma Dipine Antihypertensive Drugs Description and Business Overview
6.12.3 fujipharma Dipine Antihypertensive Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 fujipharma Dipine Antihypertensive Drugs Product Portfolio
6.12.5 fujipharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dipine Antihypertensive Drugs Industry Chain Analysis
7.2 Dipine Antihypertensive Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dipine Antihypertensive Drugs Production Mode & Process
7.4 Dipine Antihypertensive Drugs Sales and Marketing
7.4.1 Dipine Antihypertensive Drugs Sales Channels
7.4.2 Dipine Antihypertensive Drugs Distributors
7.5 Dipine Antihypertensive Drugs Customers
8 Dipine Antihypertensive Drugs Market Dynamics
8.1 Dipine Antihypertensive Drugs Industry Trends
8.2 Dipine Antihypertensive Drugs Market Drivers
8.3 Dipine Antihypertensive Drugs Market Challenges
8.4 Dipine Antihypertensive Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer